{"publication_id":"48abac66-87ee-46dd-a1e0-1a1bbcc8d12d","traces":[{"claim_id":"claim_1","claim":"The cited A/B receipts support a specific working claim: rapamycin at 42 ppm extended female median lifespan by 26%; rapamycin reduced 90th-percentile mortality by 14% in females (Harrison 2009 NIA-ITP, 14 ppm). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.","candidate_sources":[{"study":"Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction","doi":"10.1111/acel.12194","url":null},{"study":"Rapamycin fed late in life extends lifespan in genetically heterogeneous mice","doi":"10.1038/nature08221","url":null},{"study":"Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer","doi":"10.1111/acel.12496","url":null},{"study":"Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice","doi":"10.7554/eLife.16351","url":null},{"study":"Life-span Extension Drug Interventions Affect Adipose Tissue Inflammation in Aging","doi":"10.1093/gerona/glz177","url":null}]},{"claim_id":"claim_2","claim":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.","candidate_sources":[{"study":"Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction","doi":"10.1111/acel.12194","url":null},{"study":"Rapamycin fed late in life extends lifespan in genetically heterogeneous mice","doi":"10.1038/nature08221","url":null},{"study":"Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer","doi":"10.1111/acel.12496","url":null},{"study":"Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice","doi":"10.7554/eLife.16351","url":null},{"study":"Life-span Extension Drug Interventions Affect Adipose Tissue Inflammation in Aging","doi":"10.1093/gerona/glz177","url":null}]},{"claim_id":"claim_3","claim":"Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?","candidate_sources":[{"study":"Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction","doi":"10.1111/acel.12194","url":null},{"study":"Rapamycin fed late in life extends lifespan in genetically heterogeneous mice","doi":"10.1038/nature08221","url":null},{"study":"Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer","doi":"10.1111/acel.12496","url":null},{"study":"Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice","doi":"10.7554/eLife.16351","url":null},{"study":"Life-span Extension Drug Interventions Affect Adipose Tissue Inflammation in Aging","doi":"10.1093/gerona/glz177","url":null}]},{"claim_id":"claim_4","claim":"`fact_id=166319` (`A_core`) — Metformin (0.1%) combined with rapamycin (14 ppm) robustly extended lifespan, suggestive of an added benefit. doi=10.1111/acel.12496","candidate_sources":[{"study":"Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction","doi":"10.1111/acel.12194","url":null},{"study":"Rapamycin fed late in life extends lifespan in genetically heterogeneous mice","doi":"10.1038/nature08221","url":null},{"study":"Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer","doi":"10.1111/acel.12496","url":null},{"study":"Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice","doi":"10.7554/eLife.16351","url":null},{"study":"Life-span Extension Drug Interventions Affect Adipose Tissue Inflammation in Aging","doi":"10.1093/gerona/glz177","url":null}]},{"claim_id":"claim_5","claim":"`fact_id=135475` (`A_core`) — rapamycin led to a 217% and 106% increase of M1 (CD45+CD64+CD206−) ATMs in females doi=10.1093/gerona/glz177","candidate_sources":[{"study":"Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction","doi":"10.1111/acel.12194","url":null},{"study":"Rapamycin fed late in life extends lifespan in genetically heterogeneous mice","doi":"10.1038/nature08221","url":null},{"study":"Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer","doi":"10.1111/acel.12496","url":null},{"study":"Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice","doi":"10.7554/eLife.16351","url":null},{"study":"Life-span Extension Drug Interventions Affect Adipose Tissue Inflammation in Aging","doi":"10.1093/gerona/glz177","url":null}]},{"claim_id":"claim_6","claim":"_Within the currently bound receipt bundle, no A_core/B_context opposing fact was selected. Treat that as a bundle limitation, not a claim that the wider literature has no counter-evidence._","candidate_sources":[{"study":"Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction","doi":"10.1111/acel.12194","url":null},{"study":"Rapamycin fed late in life extends lifespan in genetically heterogeneous mice","doi":"10.1038/nature08221","url":null},{"study":"Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer","doi":"10.1111/acel.12496","url":null},{"study":"Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice","doi":"10.7554/eLife.16351","url":null},{"study":"Life-span Extension Drug Interventions Affect Adipose Tissue Inflammation in Aging","doi":"10.1093/gerona/glz177","url":null}]}]}